Federal Project Grant Award Summary

Thomas Jefferson University's Sidney Kimmel Medical College received a $1.1 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026 through May 31, 2030. The grant supports research investigating how chemoradiation treatment imparts KRAS-mediated resistance to immunotherapy in non-small cell lung cancer. This project contributes to the DHA's broader mission of transforming healthcare for military service members and the American public through innovative biomedical research solutions addressing critical health challenges, with particular emphasis on oncology and precision medicine applications.

As a leading academic medical center with substantial experience executing federally-funded medical research, Thomas Jefferson University will conduct hypothesis-driven research and translational investigation activities at its Philadelphia, Pennsylvania location. The four-year award aligns with typical Military Medical Research and Development program performance periods and represents the university's demonstrated capacity to deliver complex biomedical research through its established federal research enterprise, which includes prior significant funding from the National Cancer Institute, National Heart, Lung, and Blood Institute, and the Defense Health Agency for oncology-related and translational research initiatives.